Dublin, April 30, 2018 -- The "Integrated Devices for Reconstituting Injectables" report has been added to ResearchAndMarkets.com's offering.
The inherent instability of biological drugs is a limitation that has a direct impact on the drug delivery sector. Therapeutic proteins must either be stored under special conditions or formulated to retain their efficacy from the time of manufacture until they are dispensed. Liquid protein drugs require refrigeration until dispensed.
Alternatively, proteins can be formulated as powders (lyophilization) and must be reconstituted prior to injection. Historically, this was accomplished by including a disposable syringe and diluent vial for manual reconstitution. As the number of drugs developed for self-administration has grown, devices that integrate a reconstitution step with the injection step have gained traction.
As biological drugs continue to grow in terms of therapeutics and total prescriptions, the impact of specialty devices will increase.
What You Will Learn
- What is the impact of lyophilized injectable drugs on today's therapeutic market, how are they packaged, and who markets them?
- Who are the suppliers of integrated reconstitution devices, and what is their market impact?
- What are the major factors driving the demand for integrated devices for injectable drug reconstitution?
- What is the relative impact of integrated reconstitution systems to OEM or standalone reconstitution devices and how will this change by the end of the decade?
- What are the essential design factors, material selection issues, technologies and market development issues for drug reconstitution systems and devices?
- What is the role of integrated drug reconstitution systems on drug life cycle management?
- What are the significant economic, technology, and regulatory factors affecting the market for injectable drugs and reconstitution systems in particular?
Who Should Read this Report
Development
- Drug Developers
- Device Suppliers
- CMOs
- Components/APIs
- Testing/Validation
- Clinical Trial Mgmt
Industry
- Pharma Managers
- Biotech Managers
- Drug Marketers
- Industry Strategists
- Financial Analysts
- Management Consultants
Market
- Clinical Managers
- Drug Distributors
- Pharma Regulators
- FDA Consultants
- Managed Care Managers
Key Topics Covered:
1. Executive Summary
2. Drug Reconstitution Market Dynamics
- Evolution in Device Design
- Formulation Factors
- Product Specific Device Development
- Specialty Injection Device Demand Drivers
- Chronic Conditions and Self-Administration
- The Growth of Biologicals
- Formulation and Dosing
- Shifting Patient Demographics
- Drug Economics, Safety and Compliance
- Device Design and Innovation
- Competitive Landscape
- Technology Market Drivers
3. Integrated Devices for Reconstituting Injectables
- Dual Chamber Cartridges
- Dual Chamber Injectors
- Dual Chamber Syringes
- Wearable Device Automated Reconstitution System
4. Dual Chamber Syringe & Injector Device Assessments
- Product-Specific Devices
- Specialty Devices
- OEM Devices
5. Therapeutic Segments - Market Data & Forecasts
- Glycemic Control
- Hereditary Conditions
- Hormone Replacement
- Infectious Disease
- Metabolic Conditions
- Oncology
- Reproductive Health
- Other Therapeutic Segments
6. Market Factors
- Device Product Strategies
- Device Economics
- Product Branding
- Direct-to-Consumer Marketing
- Managed Care Trends
7. Company Profiles
For more information about this report visit https://www.researchandmarkets.com/research/sdhjp2/2018_integrated?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Infusions and Injectables


Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments
Samsung Surpasses $1 Trillion Market Cap Amid AI Chip Boom and Apple Partnership Talks
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure
Arm Stock Drops Despite Strong AI Chip Demand and Earnings Beat
Lufthansa Q1 Loss Narrows as Strong Summer Travel Demand Boosts Outlook
Infineon Raises 2026 Outlook as AI Data Center Chip Demand Surges
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says
Supermicro Forecasts Strong Q4 Revenue Growth as AI Server Demand Surges
Strategy Reports Q1 Loss as Bitcoin Holdings Trigger $14.46 Billion Unrealized Hit
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations
BHP Attracts AI-Focused Investors as Copper Demand Surges
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 



